Evexomostat

N/A

Report date: 2022/06/06 14:13:18
NME

Base Information

Drug NameEvexomostat
Drug Alias NameMetAP2 inhibitor (SynDevRx)Methionine aminopeptidase type II (SynDevRx)SDX-7320O-7320
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMethionine aminopeptidase 2 inhibitors
TargetsMethionine aminopeptidase 2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursInsulin Resistance +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSyndevrx Inc
China Registration ClassN/A

Develop Information

Active CompaniesSyndevrx Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerInsulin ResistanceTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A